MIRM
Mirum Pharmaceuticals, Inc.
$98.62
-2.05
(-2.04%)
Mkt Cap
4.95B
Volume
439,894
52W Range
43.3-114.99
Sector
Healthcare
Beta
0.52
EPS (TTM)
-13.61
P/E Ratio
-169.72
Revenue (TTM)
569.61M
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 521.31M | 336.89M | 186.37M | 77.06M | 19.14M | 0 | 0 | 0 |
| Net Income | (23.36M) | (87.94M) | (163.41M) | (135.66M) | (83.99M) | (103.27M) | (52.55M) | (17.35M) |
| EPS | -0.47 | -1.85 | -4.00 | -4.01 | -2.77 | -4.09 | -2.29 | -0.75 |
| Free Cash Flow | 54.87M | 9.33M | (91.05M) | (120.41M) | (151.78M) | (89.30M) | (39.64M) | (7.87M) |
| FCF / Share | 1.09 | 0.20 | -2.23 | -3.56 | -5.01 | -3.54 | -1.72 | -0.34 |
| Operating CF | 55.83M | 10.32M | (70.94M) | (120.14M) | (132.76M) | (89.08M) | (39.36M) | (373,000) |
| Total Assets | 842.81M | 670.75M | 646.62M | 352.91M | 294.65M | 240.86M | 146.71M | 51.98M |
| Total Debt | 319.45M | 317.76M | 308.14M | 2.19M | 2.61M | 3.26M | 3.65M | 0 |
| Cash & Equiv | 296.68M | 222.50M | 286.33M | 28.00M | 31.34M | 142.09M | 11.97M | 51.96M |
| Book Value | 314.69M | 225.64M | 248.67M | 142.04M | 120.21M | 172.09M | 130.35M | (10.32M) |
| Return on Equity | -0.07 | -0.39 | -0.66 | -0.96 | -0.70 | -0.60 | -0.40 | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 159.88M | 148.93M | 133.01M | 127.78M | 111.58M | 99.41M | 90.38M | 77.88M | 69.22M | 69.55M | 47.73M | 37.50M |
| Net Income | (790.15M) | (5.73M) | 2.90M | (5.86M) | (14.68M) | (23.79M) | (14.23M) | (24.64M) | (25.28M) | (35.66M) | (23.59M) | (74.04M) |
| EPS | -13.43 | -0.12 | 0.06 | -0.12 | -0.30 | -0.49 | -0.30 | -0.52 | -0.54 | -0.71 | -0.57 | -1.94 |
| Free Cash Flow | (229.43M) | 5.47M | 39.49M | 11.91M | (2.00M) | (5.09M) | (6.20M) | (14.58M) | 15.20M | (21.62M) | (18.22M) | (17.40M) |
| FCF / Share | -3.90 | 0.11 | 0.68 | 0.24 | -0.04 | -0.11 | -0.13 | -0.31 | 0.32 | -0.46 | -0.44 | -0.46 |
| Operating CF | (228.76M) | 6.07M | 39.68M | 12.04M | (1.96M) | (5.07M) | 3.98M | (3.80M) | 15.21M | (16.62M) | (18.22M) | (17.33M) |
| Total Assets | 890.92M | 842.81M | 785.12M | 725.83M | 690.25M | 670.75M | 667.89M | 660.75M | 651.96M | 646.62M | 650.64M | 443.59M |
| Total Debt | 323.78M | 319.45M | 318.76M | 318.90M | 317.16M | 317.76M | 317.65M | 316.56M | 307.52M | 308.14M | 307.97M | 307.83M |
| Cash & Equiv | 324.91M | 296.68M | 282.02M | 228.12M | 211.82M | 222.50M | 222.97M | 233.25M | 302.84M | 286.33M | 303.06M | 297.23M |
| Book Value | 242.49M | 314.69M | 292.05M | 255.16M | 233.26M | 225.64M | 232.02M | 228.99M | 234.60M | 248.67M | 269.08M | 78.61M |
| Return on Equity | -3.26 | -0.02 | 0.01 | -0.02 | -0.06 | -0.11 | -0.06 | -0.11 | -0.11 | -0.14 | -0.09 | -0.94 |
MIRM News
Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026
Mirum Pharma: A Rare Disease Growth Story to Watch
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes
Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering
Mirum Pharmaceuticals: A Rare Disease Platform Becoming Bigger Than Its First Franchise
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Mirum's Q1 Earnings & Revenues Beat Estimates, 2026 View Raised
Mirum Pharmaceuticals, Inc. (MIRM) Q1 2026 Earnings Call Transcript
Here's What Key Metrics Tell Us About Mirum Pharmaceuticals (MIRM) Q1 Earnings